Bain Capital expects to pursue more deals like its recent $300 million partnership with Bristol Myers Squibb, a source familiar with the firm's thinking tells Axios Pro.
Why it matters: The deal demonstrates PE interest in carving out new biopharma upstarts as the pharma and biotech sector faces regulatory and pipeline pressure.
